GlassScriptPhysician profile
Carl Huntoon
NPI 1649883653
$1,579.88
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $60.12 · 2022: $310 · 2023: $528 · 2024: $681.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,196 · Education: $13.69.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,196.01 |
| Education | $13.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $377.38 | 2022-2024 | Caplyta |
| Janssen Pharmaceuticals, INC | $302.98 | 2021-2024 | Spravato, Invega Trinza, Invega Sustenna |
| Alkermes, INC. | $226.05 | 2022-2024 | Aristada, Lybalvi |
| Abbvie INC. | $140.28 | 2022-2024 | |
| Otsuka America Pharmaceutical, INC. | $123.99 | 2023-2024 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $113.77 | 2023-2024 | Austedo Xr, Uzedy |
| Takeda Pharmaceuticals U.S.A., INC. | $87.58 | 2023-2024 | Trintellix |
| Axsome Therapeutics, INC. | $85.37 | 2024 | Auvelity |
| Lundbeck LLC | $42.15 | 2021-2024 | Rexulti |
| Corium, LLC | $40.47 | 2023-2024 | Azstarys |
| Neurocrine Biosciences, INC. | $21.51 | 2023 | Ingrezza |
| Vanda Pharmaceuticals INC. | $18.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carl Huntoon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.